TY  - JOUR
A1  - Lu, Yong-Ping
A1  - Hasan, Ahmed A.
A1  - Zeng, Shufei
A1  - Hocher, Berthold
T1  - Plasma ET-1 concentrations are elevated in pregnant women with hypertension - meta-analysis of clinical studies
JF  - Kidney & blood pressure research : official organ of the Gesellschaft für Nephrologie ; official organ of the Deutsche Liga zur Bekämpfung des Hohen Blutdruckes e.V., Deutsche Hypertonie-Gesellschaft
N2  - Background/Aims:
The ET system might be involved in the pathogenesis of hypertensive disorders during pregnancy. The objective is to analyse the impact of ET-1 in hypertensive pregnant women by a strict meta-analysis of published human clinical studies. 
Methods:
Based on the principle of Cochrane systematic reviews, Cohort studies in PubMed (Medline), Google Scholar and China Biological Medicine Database (CBM-disc) designed to identify the role of endothelin-1 (ET-1) in the pathophysiology of gestational hypertension and preeclampsia were screened. Review Manager Version 5.0 (Rev-Man 5.0) was applied for statistical analysis. Mean difference and 95% confidence interval (CI) were shown in inverse variance (IV) fixed-effects model or IV random-effects model.
Results:
Sixteen published cohort studies including 1739 hypertensive cases and 409 controls were used in the meta-analysis. ET-1 plasma concentrations were higher in hypertensive pregnant women as compared to the controls (mean difference between groups: 19.02 [15.60～22.44], P < 0.00001,). These finding were driven by severity of hypertension and/or degree of proteinuria.
Conclusion:
Plasma ET-1 concentrations are elevated in hypertensive disorders during human pregnancy. In particular women with preeclampsia (hypertensive pregnant women with proteinuria) have substantially elevated plasma ET-1 concentration as compared to pregnant women with normal blood pressure.
KW  - Et-1
KW  - Pregnancy
KW  - Hypertension
KW  - Meta-analysis
Y1  - 2017
U6  - https://doi.org/10.1159/000482004
SN  - 1420-4096
SN  - 1423-0143
VL  - 42
IS  - 4
SP  - 654
EP  - 663
PB  - Karger
CY  - Basel
ER  - 
TY  - JOUR
A1  - Lu, Yong-Ping
A1  - Reichetzeder, Christoph
A1  - Prehn, Cornelia
A1  - Yin, Liang-Hong
A1  - Yun, Chen
A1  - Zeng, Shufei
A1  - Chu, Chang
A1  - Adamski, Jerzy
A1  - Hocher, Berthold
T1  - Cord blood Lysophosphatidylcholine 16:1 is positively associated with birth weight
JF  - Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry and pharmacology
N2  - Background/Aims: Impaired birth outcomes, like low birth weight, have consistently been associated with increased disease susceptibility to hypertension in later life. Alterations in the maternal or fetal metabolism might impact on fetal growth and influence birth outcomes. Discerning associations between the maternal and fetal metabolome and surrogate parameters of fetal growth could give new insight into the complex relationship between intrauterine conditions, birth outcomes, and later life disease susceptibility. Methods: Using flow injection tandem mass spectrometry, targeted metabolomics was performed in serum samples obtained from 226 mother/child pairs at delivery. Associations between neonatal birth weight and concentrations of 163 maternal and fetal metabolites were analyzed. Results: After FDR adjustment using the Benjamini-Hochberg procedure lysophosphatidylcholines (LPC) 14:0, 16:1, and 18:1 were strongly positively correlated with birth weight. In a stepwise linear regression model corrected for established confounding factors of birth weight, LPC 16: 1 showed the strongest independent association with birth weight (CI: 93.63 - 168.94; P = 6.94x10(-11)). The association with birth weight was stronger than classical confounding factors such as offspring sex (CI: - 258.81- -61.32; P = 0.002) and maternal smoking during pregnancy (CI: -298.74 - -29.51; P = 0.017). Conclusions: After correction for multiple testing and adjustment for potential confounders, LPC 16:1 showed a very strong and independent association with birth weight. The underlying molecular mechanisms linking fetal LPCs with birth weight need to be addressed in future studies. (c) 2018 The Author(s) Published by S. Karger AG, Basel
KW  - Metabolomics
KW  - Lysophosphatidylcholine
KW  - Birth Weight
KW  - DOHaD
KW  - Hypertension
KW  - Type 2 Diabetes
Y1  - 2018
U6  - https://doi.org/10.1159/000487118
SN  - 1015-8987
SN  - 1421-9778
VL  - 45
IS  - 2
SP  - 614
EP  - 624
PB  - Karger
CY  - Basel
ER  -